Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

doi:10.1016/S2352-3026(15)00197-0

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

Engineering

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e516-e527
Journal	The Lancet Haematology
Volume	2
Issue number	12
DOIs	https://doi.org/10.1016/S2352-3026(15)00197-0
Publication status	Published - Dec 1 2015

ASJC Scopus Subject Areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2352-3026(15)00197-0

Cite this

@article{285ad588f6c0414f84d95ca0964d2742,

title = "Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study",

author = "Darrell White",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/S2352-3026(15)00197-0",

language = "English",

volume = "2",

pages = "e516--e527",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "12",

}

TY - JOUR

T1 - Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma

T2 - final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

AU - White, Darrell

PY - 2015/12/1

Y1 - 2015/12/1

UR - http://www.scopus.com/inward/record.url?scp=84964968270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964968270&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(15)00197-0

DO - 10.1016/S2352-3026(15)00197-0

M3 - Article

C2 - 26686406

AN - SCOPUS:84964968270

SN - 2352-3026

VL - 2

SP - e516-e527

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 12

ER -

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this